• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Made in Chi­na: TaiMed wins FDA OK for a 'break­through' HIV ther­a­py for drug-re­sis­tant pa­tients

8 years ago
Pharma

Jakobovits abrupt­ly ex­its Adicet; Stan­ford re­searchers un­cov­er mech­a­nis­tic de­tails of ALS us­ing CRISPR

8 years ago
News Briefing

Faster, more con­ve­nient Op­di­vo dos­ing sched­ules gives Bris­tol-My­ers added edge in bat­tle of the PD-1 block­busters ...

8 years ago
Pharma

View­Point Ther­a­peu­tics gets $35M to ad­vance non-sur­gi­cal al­ter­na­tive for cataracts, pres­by­opia

8 years ago
Financing

Af­ter bag­ging Shire’s cell ther­a­py castoff, Cal­adrius stock climbs

8 years ago
Pharma

Search­ing for HIV cure, Gilead­'s new 'shock and kil­l' com­bo swats back lethal virus in mon­keys

8 years ago
Discovery

Qui­et and con­fi­den­tial IPO reg­is­tra­tion? Who needs it. Au­to­lus shouts about its next big raise

8 years ago
Financing

Cam­bridge star Ma­gen­ta teams up with Hei­del­berg on bone mar­row R&D pact that in­cludes $334M in po­ten­tial mile­stones

8 years ago
R&D
Pharma

Judg­ment day is com­ing: Fed­er­al judge or­ders Mar­tin Shkre­li to for­feit a small for­tune fol­low­ing felony con­vic­tions

8 years ago
People

Glob­al CRO Parex­el woos out­sourc­ing vet­er­an Jamie Mac­don­ald to the helm

8 years ago
People
Outsourcing

Ar­cus to raise $99M IPO; Van­da wants mar­ket­ing ap­proval for jet lag

8 years ago
News Briefing

Stock flies high on Clear­side’s PhI­II mac­u­lar ede­ma tri­al re­sults as drug im­proves vi­sion

8 years ago
R&D
Pharma

Chi­nese med­i­cine play­er Tasly con­sid­ers Hong Kong IPO for its biotech arm: re­port

8 years ago
Financing
China

Watch out be­low: Der­mi­ra ax­es ac­ne drug af­ter a cat­a­stroph­ic PhI­II fail­ure

8 years ago
R&D

San­thera’s Rax­one fails NIH’s MS study in lat­est set­back, shares plunge

8 years ago
R&D

Gene edit­ing ex­pert Ho­mol­o­gy de­tails the num­bers in its back-end­ed $1B No­var­tis deal, files for $100M IPO

8 years ago
Financing

Is tech mon­ey bad for busi­ness? Sil­i­con Val­ley cash makes some bio­phar­ma VCs bris­tle, oth­ers cheer

8 years ago
Financing
Startups

Cel­gene hands over $101M in cash to launch a re­search col­lab­o­ra­tion with pro­tein play­er Vi­vid­ion

8 years ago
R&D
Pharma

Unum plays its first glimpse of hu­man da­ta in an $86M IPO, re­veal­ing two deaths and an FDA hold

8 years ago
Financing
Startups

EpimAb nabs Bin Peng from NI­BR; Jef­frey Chodake­witz ex­its Ver­tex; Chris­tiana Sta­moulis is pres­i­dent at Unum

8 years ago
Peer Review

Ac­tivist in­vestor Alex Den­ner in the spot­light again as the Med­i­cines Com­pa­ny shrinks its board

8 years ago
People

Per­lara col­lab­o­rates with Har­vard/Un­di­ag­nosed Dis­eases Net­work; Verona shares soar on pos­i­tive CF da­ta

8 years ago
News Briefing

Amid a bois­ter­ous fundrais­ing week, Bio­Med­Part­ners airs $107M biotech fund

8 years ago
Financing

Asian in­vestor com­mits $15M to launch new pro­tein degra­da­tion biotech start­up Cull­gen out of UNC

8 years ago
Startups
First page Previous page 1061106210631064106510661067 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times